Abstract
Role of clinical laboratories in response to the COVID-19 pandemic.
Highlights
Absence of adequate testing due to various factors, most significant of which being supply chain issues, is most likely contributing to community spread
Emergency Use Authorization (EUA) are accompanied by recommendations of the ideal test protocol, laboratories have to increase COVID-19 test output without compromising on accuracy yet with less than ideal variables
The pre-analytical constraints emerged as the viral transport media used for collecting nasopharyngeal (NSP) swab samples became exhausted, forcing laboratories to hold up sample collection, or revert to other collection methods
Summary
Absence of adequate testing due to various factors, most significant of which being supply chain issues, is most likely contributing to community spread. In response to the outbreak, several state authorities and commercial companies have developed diagnostic assays to test individuals for the SARS-CoV-2 infection. Over 40 diagnostic assays have received Emergency Use Authorization (EUA) from the Federal US FDA for COVID-19 testing.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
